These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 30137196)

  • 1. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
    Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
    Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
    Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
    JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
    Tibau A; Hwang TJ; Molto C; Avorn J; Kesselheim AS
    JAMA Oncol; 2024 May; 10(5):634-641. PubMed ID: 38573645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC
    Ann Oncol; 2019 Mar; 30(3):365-373. PubMed ID: 30715161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
    Mosele MF; Westphalen CB; Stenzinger A; Barlesi F; Bayle A; Bièche I; Bonastre J; Castro E; Dienstmann R; Krämer A; Czarnecka AM; Meric-Bernstam F; Michiels S; Miller R; Normanno N; Reis-Filho J; Remon J; Robson M; Rouleau E; Scarpa A; Serrano C; Mateo J; André F
    Ann Oncol; 2024 Jul; 35(7):588-606. PubMed ID: 38834388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine in breast cancer: From clinical trials to clinical practice.
    Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
    Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
    Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
    Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 11. Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
    Trapani D; Crimini E; Sandoval J; Curigliano G
    Cancer Treat Res; 2023; 188():343-351. PubMed ID: 38175352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
    Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
    Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 16. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
    Marret G; Bièche I; Dupain C; Borcoman E; du Rusquec P; Ricci F; Hescot S; Sablin MP; Tresca P; Bello D; Dubot C; Loirat D; Frelaut M; Lecerf C; Le Tourneau C; Kamal M
    JCO Precis Oncol; 2021 Nov; 5():215-226. PubMed ID: 34994597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
    Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
    BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
    Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
    Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
    Melisi D; Cavaliere A; Gobbo S; Fasoli G; Allegrini V; Simionato F; Gaule M; Casalino S; Pesoni C; Zecchetto C; Merz V; Mambrini A; Barbi E; Girelli R; Giardino A; Frigerio I; Scalamogna R; Avitabile A; Castellani S; Milella M; Butturini G
    Pancreatology; 2021 Apr; ():. PubMed ID: 33896692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.